

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 July 2023 (20.07.2023)



(10) International Publication Number
WO 2023/134733 A1

(51) International Patent Classification:

C07D 211/12 (2006.01) *A61K 31/13* (2006.01)
C07D 207/06 (2006.01) *A61P 31/12* (2006.01)
C07C 211/64 (2006.01) *A61P 29/00* (2006.01)

(21) International Application Number:

PCT/CN2023/071974

(22) International Filing Date:

12 January 2023 (12.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/072269

17 January 2022 (17.01.2022) CN

(71) Applicants: **TECHFIELDS PHARMA CO., LTD.**

[CN/CN]; Room 101, Building 9, 168 Majian Road, Gaixin District, Suzhou, Jiangsu 215129 (CN). **TECHFIELDS INC.** [US/US]; 731 Alexander Road, Princeton, New Jersey 08540 (US).

(72) Inventors: **YU, Chongxi**; 731 Alexander Road, Suite 205, Princeton, New Jersey 08540 (US). **XU, Lina**; 168 Majian Road, Building 9, Room 401, Gaixin District, Suzhou, Jiangsu 215129 (CN).

(74) Agent: **BEIJING WANHUIDA LAW FIRM**; 2F, Yiyuan Office, Friendship Hotel, No.1 Zhongguancun Street South, Haidian District, Beijing 100873 (CN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: TREATMENT OF SIGNS, SYMPTOMS AND/OR COMPLICATIONS OF VIRAL, BACTERIAL, PROTOZOAL, AND/OR FUNGAL INFECTIONS BY HIGH PENETRATION PRODRUGS




Figure 1

(57) Abstract: High penetration prodrugs (HPPs), pharmaceutical compositions and methods thereof, for treatment of signs, symptoms and/or complications of viral, bacterial, protozoal, and/or fungal infections are disclosed. The HPPs are capable of penetrating one or more biological barriers to reach areas that their corresponding parent drugs may not be able to reach with sufficient quantities. While the HPPs can be administered to a subject through various administration routes, e.g., local delivery or systemic administration, transdermal or topical administration of them provides various additional advantages over use of the parent drugs.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*